Literature DB >> 27079723

Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.

Siobhan M Hoscheidt1, Erika J Starks1, Jennifer M Oh1, Henrik Zetterberg2,3, Kaj Blennow2, Rachel A Krause1, Carey E Gleason4,1, Luigi Puglielli1,4, Craig S Atwood4,1, Cynthia M Carlsson4,1,5, Sanjay Asthana4,1,5, Sterling C Johnson4,1,5, Barbara B Bendlin1,5.   

Abstract

BACKGROUND: Type 2 diabetes is associated with an increased risk for Alzheimer's disease (AD). Regulation of normal insulin function may be important in reducing the prevalence of dementia due to AD, particularly in individuals who harbor genetic risk for or have a parental family history of AD. The relationship between insulin resistance (IR) and AD pathology remains poorly understood, particularly in midlife prior to the onset of clinical metabolic disease or cognitive decline.
OBJECTIVE: We examined associations between IR as indexed by HOMA-IR, cerebrospinal fluid (CSF) biomarkers of AD pathology, and memory in middle-aged adults enriched for AD. We postulated that higher HOMA-IR and APOEɛ4 carriage would be associated with greater CSF AD pathology and poor memory performance.
METHODS: Cognitively asymptomatic middle-aged adults (N = 70, mean age = 57.7 years) from the Wisconsin Alzheimer's Disease Research Center with a parental family history of dementia due to AD underwent lumbar puncture, blood draw, and neuropsychological testing. CSF AD biomarkers including soluble amyloid-β protein precursor β (sAβPPβ), amyloid-β42 (Aβ42), and phosphorylated tau (P-tau181) were examined with respect to HOMA-IR and APOEɛ4 status. Delayed memory performance was examined with respect to HOMA-IR, CSF AD biomarkers, and APOEɛ4 status.
RESULTS: Higher HOMA-IR was associated with higher sAβPPβ and Aβ42 . APOEɛ4 carriers had significantly higher levels of sAβPPα, sAβPPβ, and P-tau181/Aβ42 compared to noncarriers. The concurrent presence of higher HOMA-IR and CSF AD pathology predicted worse delayed memory performance.
CONCLUSION: Overall, the findings suggest that IR and APOEɛ4 are contributing factors to the development of AD pathology in midlife, and provide support for targeting insulin function as a potentially modifiable risk factor for AD.

Entities:  

Keywords:  APOEɛ4; CSF AD biomarkers; insulin resistance; memory function

Mesh:

Substances:

Year:  2016        PMID: 27079723      PMCID: PMC5066305          DOI: 10.3233/JAD-160110

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  77 in total

1.  The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study.

Authors:  Otto Tschritter; Hubert Preissl; Anita M Hennige; Michael Stumvoll; Katarina Porubska; Rebekka Frost; Hannah Marx; Benjamin Klösel; Werner Lutzenberger; Niels Birbaumer; Hans-Ulrich Häring; Andreas Fritsche
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-28       Impact factor: 11.205

Review 2.  Impaired insulin action in the human brain: causes and metabolic consequences.

Authors:  Martin Heni; Stephanie Kullmann; Hubert Preissl; Andreas Fritsche; Hans-Ulrich Häring
Journal:  Nat Rev Endocrinol       Date:  2015-10-13       Impact factor: 43.330

Review 3.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Authors:  Robert W Mahley; Karl H Weisgraber; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

4.  Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype.

Authors:  S Craft; S Asthana; G Schellenberg; L Baker; M Cherrier; A A Boyt; R N Martins; M Raskind; E Peskind; S Plymate
Journal:  Ann N Y Acad Sci       Date:  2000-04       Impact factor: 5.691

Review 5.  Regulation of APP cleavage by alpha-, beta- and gamma-secretases.

Authors:  J Nunan; D H Small
Journal:  FEBS Lett       Date:  2000-10-13       Impact factor: 4.124

6.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function.

Authors:  Zoe Arvanitakis; Robert S Wilson; Julia L Bienias; Denis A Evans; David A Bennett
Journal:  Arch Neurol       Date:  2004-05

7.  Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging.

Authors:  Madhav Thambisetty; E Jeffrey Metter; An Yang; Hillary Dolan; Christopher Marano; Alan B Zonderman; Juan C Troncoso; Yun Zhou; Dean F Wong; Luigi Ferrucci; Josephine Egan; Susan M Resnick; Richard J O'Brien
Journal:  JAMA Neurol       Date:  2013-09-01       Impact factor: 18.302

8.  Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease.

Authors:  Auriel A Willette; Barbara B Bendlin; Erika J Starks; Alex C Birdsill; Sterling C Johnson; Bradley T Christian; Ozioma C Okonkwo; Asenath La Rue; Bruce P Hermann; Rebecca L Koscik; Erin M Jonaitis; Mark A Sager; Sanjay Asthana
Journal:  JAMA Neurol       Date:  2015-09       Impact factor: 18.302

9.  Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease.

Authors:  R A Honea; R H Swerdlow; E D Vidoni; J Goodwin; J M Burns
Journal:  Neurology       Date:  2010-01-12       Impact factor: 9.910

10.  Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease.

Authors:  V W Henderson
Journal:  Climacteric       Date:  2014-08-17       Impact factor: 3.005

View more
  24 in total

Review 1.  Disturbed sleep and diabetes: A potential nexus of dementia risk.

Authors:  Calliope Holingue; Alexandra Wennberg; Slava Berger; Vsevolod Y Polotsky; Adam P Spira
Journal:  Metabolism       Date:  2018-02-01       Impact factor: 8.694

2.  Neurocognition in treatment-resistant hypertension: profile and associations with cardiovascular biomarkers.

Authors:  Patrick J Smith; James A Blumenthal; Alan L Hinderliter; Stephanie M Mabe; Jeanne E Schwartz; Forgive Avorgbedor; Andrew Sherwood
Journal:  J Hypertens       Date:  2019-05       Impact factor: 4.844

Review 3.  Review: Relationship of type 2 diabetes to human brain pathology.

Authors:  J J Pruzin; P T Nelson; E L Abner; Z Arvanitakis
Journal:  Neuropathol Appl Neurobiol       Date:  2018-03-04       Impact factor: 8.090

4.  Linking Alzheimer's disease and type 2 diabetes: Novel shared susceptibility genes detected by cFDR approach.

Authors:  Xia-Fang Wang; Xu Lin; Ding-You Li; Rou Zhou; Jonathan Greenbaum; Yuan-Cheng Chen; Chun-Ping Zeng; Lin-Ping Peng; Ke-Hao Wu; Zeng-Xin Ao; Jun-Min Lu; Yan-Fang Guo; Jie Shen; Hong-Wen Deng
Journal:  J Neurol Sci       Date:  2017-08-01       Impact factor: 3.181

5.  Palmitic Acid-Induced NAD+ Depletion is Associated with the Reduced Function of SIRT1 and Increased Expression of BACE1 in Hippocampal Neurons.

Authors:  Manuel Flores-León; Martha Pérez-Domínguez; Rodrigo González-Barrios; Clorinda Arias
Journal:  Neurochem Res       Date:  2019-05-09       Impact factor: 3.996

6.  Effect of APOE ε4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease.

Authors:  Jill K Morris; Roxanne Adeline Z Uy; Eric D Vidoni; Heather M Wilkins; Ashley E Archer; John P Thyfault; John M Miles; Jeffrey M Burns
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 7.  Insulin resistance in Alzheimer's disease.

Authors:  Thomas Diehl; Roger Mullins; Dimitrios Kapogiannis
Journal:  Transl Res       Date:  2016-12-13       Impact factor: 7.012

Review 8.  Impaired insulin signalling and allostatic load in Alzheimer disease.

Authors:  Fernanda G De Felice; Rafaella A Gonçalves; Sergio T Ferreira
Journal:  Nat Rev Neurosci       Date:  2022-02-28       Impact factor: 34.870

Review 9.  Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?

Authors:  Molly Stanley; Shannon L Macauley; David M Holtzman
Journal:  J Exp Med       Date:  2016-07-18       Impact factor: 14.307

10.  Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.

Authors:  Stefan L C Geijselaers; Pauline Aalten; Inez H G B Ramakers; Peter Paul De Deyn; Annemieke C Heijboer; Huiberdina L Koek; Marcel G M OldeRikkert; Janne M Papma; Fransje E Reesink; Lieke L Smits; Coen D A Stehouwer; Charlotte E Teunissen; Frans R J Verhey; Wiesje M van der Flier; Geert Jan Biessels
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.